Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE)

A. Stigliano, I. Chiodini, R. Giordano, A. Faggiano, L. Canu, S. Della Casa, P. Loli, M. Luconi, F. Mantero, M. Terzolo

Research output: Contribution to journalArticle

Abstract

1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.

Original languageEnglish
Pages (from-to)103-121
Number of pages19
JournalJournal of Endocrinological Investigation
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Adjuvant treatment
  • Adrenocortical carcinoma
  • Mitotane
  • Overall survival
  • Prognostic factors
  • Recurrence-free survival

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE)'. Together they form a unique fingerprint.

  • Cite this